449 related articles for article (PubMed ID: 26991743)
1. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
[TBL] [Abstract][Full Text] [Related]
2. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
3. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
[TBL] [Abstract][Full Text] [Related]
4. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
Chu FM; Jayson M; Dineen MK; Perez R; Harkaway R; Tyler RC
J Urol; 2002 Sep; 168(3):1199-203. PubMed ID: 12187267
[TBL] [Abstract][Full Text] [Related]
5. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
[TBL] [Abstract][Full Text] [Related]
6. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
Crawford ED; Moul JW; Sartor O; Shore ND
Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
[TBL] [Abstract][Full Text] [Related]
7. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
8. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.
Shore N; Mincik I; DeGuenther M; Student V; Jievaltas M; Patockova J; Simpson K; Hu CH; Huang ST; Li Y; Lee Y; Chien B; Mao J
World J Urol; 2020 Jan; 38(1):111-119. PubMed ID: 30941562
[TBL] [Abstract][Full Text] [Related]
9. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
Sartor O; Dineen MK; Perez-Marreno R; Chu FM; Carron GJ; Tyler RC
Urology; 2003 Aug; 62(2):319-23. PubMed ID: 12893343
[TBL] [Abstract][Full Text] [Related]
10. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
11. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
[TBL] [Abstract][Full Text] [Related]
12. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
Lim CN; Salem AH
Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies.
Spitz A; Gittelman M; Karsh LI; Dragnic S; Soliman AM; Lele A; Gruca D; Norton M
Res Rep Urol; 2016; 8():159-64. PubMed ID: 27602344
[TBL] [Abstract][Full Text] [Related]
14. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer.
Sharifi R; Browneller R;
J Urol; 2002 Sep; 168(3):1001-4. PubMed ID: 12187208
[TBL] [Abstract][Full Text] [Related]
15. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
16. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
Sharifi R; Knoll LD; Smith J; Kramolowsky E
Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
[TBL] [Abstract][Full Text] [Related]
18. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
[TBL] [Abstract][Full Text] [Related]
20. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
